UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.10 Million Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 6.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 237,735 shares of the company's stock after selling 17,102 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.28% of Progyny worth $4,101,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC boosted its stake in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after purchasing an additional 1,355 shares in the last quarter. Caitlin John LLC lifted its holdings in shares of Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after buying an additional 3,183 shares during the period. Natixis acquired a new stake in shares of Progyny in the fourth quarter valued at $69,000. SBI Securities Co. Ltd. bought a new position in Progyny during the fourth quarter valued at about $74,000. Finally, KBC Group NV grew its holdings in Progyny by 84.6% during the fourth quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after acquiring an additional 2,140 shares during the period. Institutional investors and hedge funds own 94.93% of the company's stock.

Analysts Set New Price Targets

PGNY has been the subject of a number of research analyst reports. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a report on Monday, March 31st. Canaccord Genuity Group dropped their target price on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Finally, Bank of America raised their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $23.45.

Progyny Stock Up 1.5%

Shares of Progyny stock traded up $0.32 during trading on Friday, hitting $21.68. The stock had a trading volume of 509,321 shares, compared to its average volume of 1,710,718. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $30.42. The stock has a 50 day simple moving average of $22.02 and a 200 day simple moving average of $20.43. The company has a market capitalization of $1.86 billion, a PE ratio of 37.38, a P/E/G ratio of 2.39 and a beta of 1.32.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $324.04 million during the quarter, compared to analyst estimates of $307.86 million. During the same period last year, the business earned $0.17 EPS. The business's quarterly revenue was up 16.5% on a year-over-year basis. As a group, equities analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.